At today's web-cast, Mr. Hassan highlighted Schering's top three not-yet-US-approved drug candidates -- including Bridion, or sugammadex:
. . ..We believe we're hitting the sweet spot on R&D and patent exclusivity. . . .
-- Fred Hassan,
November 24, 2008
But wait, Fred -- FDA rejected that application -- in June 2008. I know you are working on it with FDA -- just as three years ago, you predicted the launch, in 2009 to 2010 of several of the drug candidates you now "aspire" to have initially-filed with FDA. So, each of those is about three to four years behind where you earlier said each would be.
Gee, that's an oddly-shapen "sweet spot", Mr. Hassan.